Investors

investor people image

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers
COLUMBIA, Md. , July 11, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced the initiation of its “Multicenter, Prospective, Randomized,
View HTML
Toggle Summary Osiris Announces Implementation of Prestige Lyotechnology℠ Preservation Method Allowing Ambient Storage of Living Tissues
COLUMBIA, Md. , June 04, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today the implementation of Prestige Lyotechnology for manufacturing
View HTML
Toggle Summary Osiris Announces New Peer-Reviewed Publication Summarizing Clinical Outcomes of Viable Cryopreserved Placental Membranes for Management of Chronic Diabetic Foot Ulcers in Real World Setting
COLUMBIA, Md. , April 25, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled “Effectiveness of
View HTML
Toggle Summary Osiris Therapeutics to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care and Wound Healing Society Spring Conference
Experts to host a variety of presentations from April 25 – April 29, 2018, in Charlotte, North Carolina COLUMBIA, Maryland , April 24, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for
View HTML
Toggle Summary Osiris Appoints Willi Miesch to its Board of Directors, Change in CEO
COLUMBIA, Md. , Feb. 06, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on February 6 th , 2018, appointed Mr. Willi Miesch as a Director, upon recommendation of the Nominating Committee.  Mr.
View HTML
Toggle Summary Osiris Therapeutics, Inc. Announces Resolution of SEC Investigation
COLUMBIA, Md. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR) (the "Company"), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced the resolution of the previously
View HTML
Toggle Summary Osiris Therapeutics, Inc. Provides Update on Audit of 2015 and 2016 Financial Statements
COLUMBIA, Md. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR) (the "Company"), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today provided an update regarding the status of the
View HTML
Toggle Summary Osiris Announces a Peer-Reviewed Publication of a Scientific Study Reporting Antimicrobial Properties of Human Cryopreserved Viable Amniotic Membrane
COLUMBIA, Md. , Oct. 23, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today a scientific publication of "Antimicrobial Peptides
View HTML
Toggle Summary Osiris Therapeutics to Present 10 Advanced Clinical and Scientific Abstracts, Including an Exclusive Oral Presentation on its New Ambient Viable Tissue Preservation Technology
Experts to host a variety of presentations at Symposium on Advanced Wound Care Fall Meeting, October 20 - October 22, 2017, in Las Vegas, Nevada
View HTML
Toggle Summary Osiris Announces a Peer-Reviewed Publication Reporting the Use of Placental Membranes for Refractory Cutaneous Sinus Tracts of Surgical Origin
COLUMBIA, Md. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer reviewed manuscript entitled
View HTML